LAMEA silent heart attack market is estimated to grow at a CAGR of around 5.4% during the forecast period. Rising incidence and prevalence rate of CVD, CHD, and other heart conditions are creating the demand for the diagnosis and treatment of silent heart attacks in the LAMEA region. As per the data published by the Ministry of Health and Prevention (MOHAP), in September 2019, the prevalence of hypertension in UAE has recorded 28.8%. This represents a significant number of hypertensive patients in the country. Likewise, rising hypertension among patients in South Africa is expected to boost the adoption of diagnosis and treatment procedures to reduce the possibility of occurrence of severe conditions, including heart attack. The prevalence of hypertension is rising in Latin American countries owing to the significant rise in obese and overweight population, sedentary lifestyle coupled with the excessive consumption of alcohol and tobacco. As per the survey conducted by the Ministry of Health (Brazil), the obesity rate in Brazil was increased from 11.8% to 19.8% between 2006 and 2018.
To learn more about this report request a sample copy @ https://www.omrglobal.com/industry-reports/lamea-silent-heart-attack-market
LAMEA silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Surgery is most commonly required to increase blood flow through a blocked artery. Therefore, angioplasty and bypass surgery are significantly used for the management of blocked arteries and improve blood flow to the heart.
The companies which are contributing to the growth of the LAMEA silent heart attack market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Pfizer Inc., Terumo Corp., and Teva Pharmaceutical Industries Ltd. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
LAMEA Silent Heart Attack Market- Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of LAMEA Silent Heart Attack Market is available at: https://www.omrglobal.com/industry-reports/lamea-silent-heart-attack-market
